Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
Season 5, Episode 4, Mar 01, 03:45 PM
In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.